GTx to continue phase 3 trials of Acapodene for prostate cancer

By Lisa Kerner

Charlotte, N.C., Sept. 5 - GTx, Inc. said it will continue its planned clinical development, including two pivotal phase 3 trials of Acapodene (toremifene citrate), as recommended by an independent drug safety monitoring board following a safety review.

More than 2,700 patients are enrolled in the two phase 3 trials, according to a news release.

The Memphis, Tenn.-based biotechnology company is developing Acapodene for the treatment of multiple side effects of androgen deprivation therapy for prostate cancer and for the prevention of prostate cancer in men with high-grade prostatic intraepithelial neoplasia.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.